Table 1 Guidance for RSV IP in preterm infantsa.

From: Respiratory syncytial virus hospitalizations in US preterm infants after the 2014 change in immunoprophylaxis guidance by the American Academy of Pediatrics

Preterm infants

AAP 2009 guidance [35]

AAP 2014 guidance [34]

NPA 2018 guidelines [53]

<29 wGA

<12 months of age at season start

<12 months of age at season start

<12 months of age at season start

29–31 wGA

<6 months of age at season start

Not recommended

<6 months of age at season start

32–35 wGA

<3 months with identified risk factors in those 32 to <35 wGAb

Not recommended

<6 months of age at season start (includes 35 wGA infants) with significant provider-identified risk factorsc

  1. AAP American Academy of Pediatrics, IP immunoprophylaxis, NPA National Perinatal Association, RSV respiratory syncytial virus, wGA weeks’ gestational age.
  2. aPalivizumab is approved for all ≤35 wGA infants aged ≤6 months at the beginning of RSV season [4].
  3. bChildcare attendance or one or more siblings <5 years of age.
  4. cChildcare attendance, one or more school-aged siblings, twin or greater multiple gestation, young chronological age at the start of RSV season, and parental smoking.
Back to article page